SeaStar Medical Holding Corp — Investor Relations & Filings

SeaStar Medical Holding Corp. is a commercial-stage medical technology company developing therapies for critically ill patients experiencing organ failure due to hyperinflammation. The company's primary product is the Selective Cytopheretic Device (SCD), a proprietary platform therapy designed to mitigate the effects of a dysregulated immune response, often called a cytokine storm. The SCD is an immunomodulatory device that selectively targets and neutralizes the most highly activated neutrophils and monocytes responsible for destructive inflammation. It is designed to integrate with existing hemodialysis systems to alter disease progression, reduce dependency on dialysis, and shorten stays in the intensive care unit for patients with conditions such as acute kidney injury.